Press Releases and Events
PRESS RELEASES
Press Release | January 10, 2024
Press Release | January 3, 2024
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
READ MORE
Press Release | December 18, 2023
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
READ MORE
Press Release | December 11, 2023
Crinetics Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | November 21, 2023
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
READ MORE
Press Release | November 10, 2023
Crinetics Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | November 7, 2023
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
READ MORE
Press Release | October 10, 2023
Crinetics Announces October 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | September 20, 2023
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
READ MORE
Press Release | September 12, 2023
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
READ MORE
SIGN UP
WEBCAST
PRESENTATIONTransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
You are now leaving Crinetics.com
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
